Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$29.1B
151M shares
52-week range
$88.00 – $207.00
86% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
www.illumina.comNo one on the platform currently holds ILMN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 972,642 | $119.9M |
| Bridgewater Associatesas of 2026-03-31 | 12,751 | $1.6M |
| Execution date | Ratio |
|---|---|
| 2008-09-23 | 2-for-1 |
No one on the platform has traded ILMN yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.6B | +7.1% | $5.31 | $5.17–$5.43 | 35.9× | 11 |
| 2027 | $4.9B | +5.8% | $6.01 | $5.63–$6.58 | 31.8× | 12 |
| 2028 | $5.2B | +6.9% | $6.93 | $6.45–$7.71 | 27.5× | 7 |
| 2029 | $5.7B | +9.5% | $8.04 | $7.85–$8.33 | 23.7× | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.23 | $1.31 | +6.5% |
| 2026-04-30 | $1.05 | $1.15 | +9.5% |
| 2026-02-05 | $1.24 | $1.35 | +8.9% |
| 2025-10-30 | $1.17 | $1.34 | +14.5% |
| 2025-07-31 | $1.02 | $1.19 | +16.7% |
| 2025-05-08 | $0.94 | $0.97 | +3.2% |
| 2025-02-06 | $0.92 | $0.86 | -6.5% |
| 2024-11-04 | $0.88 |
| $1.14 |
| +29.7% |
| $12.8B |
| — |
| LHLabcorp Holdings Inc. | $322.59 | -0.28% | $26.5B | — |
| MEDPMedpace Holdings, Inc. | $581.95 | -2.52% | $16.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Wall St is expecting 1.36 EPS for $ILMN Q3 [Reporting 10/29 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$CFG $GFI $BIIB $RDDT $ILMN Citizens Financial strengthens banking operations, Gold Fields benefits from higher gold prices, Biogen advances neurological therapies, Reddit continues improving advertising monetization, and Illumina leads genomic sequencing.
View on StockTwits ↗$ILMN $CBOE $RMD $TDY $CFG Illumina leads genomic sequencing, Cboe Global Markets benefits from exchange activity, ResMed dominates sleep therapy, Teledyne expands industrial technology, and Citizens Financial strengthens banking operations.
View on StockTwits ↗$ILMN Canaccord Genuity raises target price to $205 from $190 Citigroup raises target price to $113 from $95 Piper Sandler raises target price to $225 from $200
View on StockTwits ↗$ILMN $CBOE $RMD $TDY $CFG Illumina leads genomic sequencing, Cboe Global Markets benefits from exchange activity, ResMed dominates sleep therapy, Teledyne expands industrial technology, and Citizens Financial strengthens banking operations.
View on StockTwits ↗this dude has been pretty spot on. so that leaves lng sofi rddt pstg (now everpure) snow scco from his predictions. i don't think snow qualifies due to non gaap profitability and i think scco they avoid for some reason. so that leaves lng sofi rddt (we don't care about midcaps like everpure). and i'd add alny be afrm hei alab rkt. spacex is a shoe in next year... which might make it worth buying right around spring next year given it will be eligible and therefore bought up. well longing a midcap 400 right now would work if we know it's the one they're picking in the september rebalance. but which one? ilumina? twilio? fti? everpure? crs? cw? it'll be one of the top 5. and it will become clearer as august goes on. maybe $ILMN is my guess.
View on StockTwits ↗$ILMN Positive (78%): shares face moderate upward pressure because the reported Q2 revenue and non-GAAP earnings beats, together with full-year revenue guidance above consensus, give analysts reason to raise forward sales and earnings estimates... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/cab69108cf04f682?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗@ZY786 @EBE_day @cubie @Jeremymartin007 @simon58 @jenbunn @ribbey @TraderRapp @tonyctl @zuby34 $ILMN wouldn’t pop because it’s already in the midcap 400 index
View on StockTwits ↗$ILMN reported 1.31 EPS and 1,159 revenue for Q2. http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_content=ILMN&utm_
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.